EGFR and glioblastoma: We verified that EGFR amplification did not have significant impact in the overall survival of patients with GBM IDH-wildtype and astrocytoma IDH-wildtype, (p = 0.393 and p = 0.522, respectively) (Fig. 3a and b), as well as, TERT promoter mutations in GBM IDH-wildtype (p = 0.605), although the number of cases was too small for conclusive results (Fig. 3c).